Core Viewpoint - Haosen Pharmaceutical reported strong financial performance for the first half of 2025, achieving record revenue and profit levels since its listing, driven by robust market demand and effective production optimization [2][3]. Financial Performance - The company achieved operating revenue of 242 million yuan, a year-on-year increase of 14.93% [2]. - Net profit attributable to shareholders reached 60.79 million yuan, up 4.74% year-on-year [2]. - Deducting non-recurring gains and losses, the net profit was 59.25 million yuan, reflecting a growth of 4.82% [2]. Market Dynamics - Haosen Pharmaceutical experienced strong order volumes for its main products, indicating a favorable supply-demand balance [2]. - The company reported a significant increase in overseas sales, which rose by 53.04% year-on-year, highlighting successful international market expansion [2]. Research and Development - R&D investment amounted to 17.71 million yuan, representing 7.32% of operating revenue, with a year-on-year increase of 52.83% [2]. - The company is actively pursuing diverse channels for R&D成果转化, aiming to convert research outcomes into market value [2]. - As of the reporting period, there are 17 products under development, including APIs and intermediates targeting various therapeutic areas [2]. Strategic Initiatives - Haosen Pharmaceutical signed an investment cooperation agreement with the Dongyang Economic Development Zone to establish a new production facility [3]. - The new facility will include a project for the annual production of 300 tons of A-40 (Atorvastatin Calcium) [3]. - The company's R&D center and office building are expected to be operational by the end of September 2025, enhancing its R&D capabilities and production capacity [3].